Extended-release hydrocodone: the devil in disguise or just misunderstood?
Ann Pharmacother
; 48(10): 1362-5, 2014 Oct.
Article
em En
| MEDLINE
| ID: mdl-25164521
ABSTRACT
Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of Pain Management has released a position statement on this medication, and individual opinion varies. Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER's limited clinical utility may make the controversy associated with its approval a moot point. As with other opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hidrocodona
/
Entorpecentes
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Ann Pharmacother
Assunto da revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Estados Unidos